BioPharma
Overdue Last read · last published · next check
Last read 12 hours ago, longer than this feed's 1 hour schedule.
Pasatru's approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.
Moderna gained $45 billion in market value in a single day, a surge that brought the company's stock to levels not seen since 2024 - and saddled it with expectations that may be tough to meet.
The clearance of Genglycos for a rare glycogen storage disease gives Ultragenyx a sellable voucher and momentum ahead of an eagerly anticipated study readout.
Heidi Overton, a medical doctor and veteran of the America First think tank, currently serves as deputy director of the White House Domestic Policy Council.
At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna shares.
The Alesta buyout helps restock BioMarin's pipeline with an asset it says could "reach our largest addressable patient population," joining other muscle and skeletal disease treatments in development.
A combination of AstraZeneca's Tagrisso and Hutchmed's Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.
Tanabe Pharma has already asked the FDA to approve the medicine for two conditions that cause severe reactions to sunlight.
A late-stage trial found the drug, which Amylyx bought for cheap in a bankruptcy auction, was effective at regulating blood sugar in patients who'd just undergone bariatric surgery.
The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments.
